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Aims Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efﬁcacy of the
oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with
acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).
Methods
and results
Patients with ACS (n ¼ 241) or high-risk CAD (n ¼ 263) received E5555 (50, 100, or 200 mg) or placebo once daily
for 12 (ACS patients) or 24 weeks (CAD patients). The incidence of TIMI major, minor, and minimal bleeds requiring
medical attention was similar in the placebo and combined E5555 (atopaxar) groups (ACS: 6.6% placebo vs. 5.0%
E5555; CAD: 1.5% placebo vs. 1.5% E5555). There were no TIMI major bleeds and three CURE major bleeds
(two with placebo; one with 100 mg E5555). There was a numerical increase in ‘any’ TIMI bleeding with the
E5555 200 mg dose (ACS: 16.4% placebo vs. 23.0% E5555, P ¼ 0.398; CAD: 4.5% placebo vs. 13.2% E5555,
P ¼ 0.081). The rate of major cardiovascular adverse events in the combined E5555 group was not different from
placebo (ACS: 6.6% placebo vs. 5.0% E5555, P ¼ 0.73; CAD: 4.5% placebo vs. 1.0% E5555, P ¼ 0.066). There was
a statistically signiﬁcant dose-dependent increase in liver function abnormalities and QTcF with E5555. At trough
dosing levels in both populations, mean inhibition of platelet aggregation was .90% with 100 and 200 mg E5555,
and 20–60% with 50 mg E5555.
Conclusion E5555 (50, 100, and 200 mg) did not increase clinically signiﬁcant bleeding, although there was a higher rate of any
TIMI bleeding with the highest two doses. All doses tested achieved a signiﬁcant level of platelet inhibition. There was
a signiﬁcant dose-dependent increase in liver function abnormalities and QTcF. Although further study is needed,
PAR-1 antagonism may have the potential to be a novel pathway for platelet inhibition to add on to the current
standard of care therapy.
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Atherothrombosis is the leading cause of death in the industrialized
world, and in many countries, including Japan, the incidence of
atherothrombosis is increasing as socio-economic changes lead
to an increase in coronary risk factors.
1–4 Atherothrombosis
involves the sudden rupture of an atherosclerotic plaque within a
diseased blood vessel, leading to platelet activation, thrombus for-
mation, and inﬂammation, which culminate in partial or complete
occlusion of blood vessels.
5
Platelets play a central role in the progression of atherothrom-
bosis
6–9 and have become a key target for therapeutic interven-
tion.
10 Agents that inhibit platelet activation, such as aspirin
11
and P2Y12 5′-adenosine diphosphate (ADP) receptor antagonists,
12
are included in management guidelines for acute coronary syn-
drome (ACS)
13 and coronary artery disease (CAD).
14 However,
these agents do not inhibit the thrombin receptor, which is one
of the most potent receptors for platelet activation.
15 Thus, plate-
lets can still be activated and aggregated through thrombin recep-
tor stimulation, even though the P2Y12 ADP receptor- and
TxA2-related activation pathways are blocked by the current stan-
dard of care treatment.
Thrombin mediates its effects through protease-activated recep-
tor 1 (PAR-1) on the platelet surface. Inhibition of PAR-1 rep-
resents a novel approach for reducing platelet activation,
16 which
spares other thrombin-mediated effects associated with haemo-
stasis.
17 E5555 (atopaxar) (Figure 1) is a low-molecular-weight
inhibitor of PAR-1 which has been shown to inhibit platelet aggre-
gation in vivo without causing prolongation of bleeding time.
18–20
Other PAR-1 inhibitors revealed antithrombotic activity in an
arterio-venous shunt model without lengthening bleeding time.
21
Here, we evaluated the safety and tolerability of oral E5555 in
two multicentre, randomized, double-blind, placebo-controlled
Phase II studies in Japanese patients with ACS or high-risk CAD.
Methods
Study design and patient population
J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect
of Thrombin) studies were two randomized, double-blind, placebo-
controlled, parallel-group, Phase II trials which included 12-week treat-
ment for ACS patients (ClinicalTrial.gov identiﬁer: NCT00619164) and
24-week treatment for CAD patients (ClinicalTrial.gov identiﬁer:
NCT00540670). Patients were eligible if they were 45–80 years of age.
For the ACS study, patients were inpatients with non-ST-elevation
myocardial infarction (NSTEMI) or unstable angina (UA), with their
last symptom occurring within 24 h prior to enrolment in the study.
To be eligible for the study, patients needed to have a new or aggra-
vated episode of ischaemic chest pain or have developed any ischaemic
symptom at rest or on light activity (such as chest pain lasting for 5 min
or longer or requiring sublingual administration of nitrate or a similar
treatment). In addition, patients needed to meet one of the following
criteria at hospitalization: troponin T, troponin I, or CK-MB .ULN
(upper limit of normal) of the institution; ischaemic changes on elec-
trocardiogram (ECG), such as ST depression ≥1 mm (adjacent two
leads), inverted T-wave ≥3 mm, or transient elevation of ST not
lasting 20 min.
For the CAD study, patients had conﬁrmed CAD deﬁned as one of
the following: post-ACS or percutaneous coronary intervention (PCI)
(.4 weeks), post-CABG (.12 weeks), angina with documented
ischaemia (by ECG or imaging), or angiographically documented steno-
sis ≥70% of a coronary vessel. Patients also had to be in a high-risk
group for CAD, with a history of treatment for diabetes mellitus, a
documented history of peripheral artery disease, or a documented
history of atherothrombotic transient ischaemic attack (TIA) or
stroke for more than 1 year prior to inclusion. All patients had to
be receiving aspirin (75–325 mg) for at least 4 weeks before screening.
Major exclusion criteria in both studies were: history of an acquired
or congenital bleeding disorder (including coagulopathy or abnormal
platelets), history of intracranial bleeding, history of ischaemic cerebral
infarction or TIA within the past year or known structural cerebral vas-
cular lesion, evidence of active pathological bleeding at screening or
history of bleeding (such as gastrointestinal or genitourinary) from
an unknown cause within 24 weeks prior to screening, unstable dia-
betes mellitus, signiﬁcant renal impairment deﬁned as serum creatinine
.2.0 mg/dL (.176 mmol/L), NYHA class III or IV cardiac failure,
documented history of chronic liver disease and/or screening
alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
.3× ULN or total bilirubin .1.5× ULN, oral anticoagulants, or
ﬁbrinolytics.
Study protocol
At each site, the study was approved by the Institutional Review Board.
All patients included in the study provided written informed consent.
Patients were randomly assigned to four groups (placebo, 50, 100,
or 200 mg E5555), received study drug orally once daily for 12
weeks (ACS patients) or 24 weeks (CAD patients), and were followed
up for up to 4 weeks after the ﬁnal dose. In the ACS study, patients
received placebo (placebo group) or 400 mg E5555 (all E5555
groups) as a loading dose on Day 1 immediately after randomization.
The primary safety endpoint was the incidence of bleeding events.
Bleeding severity was classiﬁed according to the CURE (major and
minor bleeding)
22 and TIMI (major, minor, and minimal bleeding)
23
deﬁnitions (Appendix 1). Bleeding events were adjudicated by the
Clinical Evaluation Committee (CEC) which consisted of four
blinded members who were not investigators. The secondary endpoint
was the incidence of major cardiovascular adverse events (MACEs),
such as cardiovascular death, MI, stroke, or recurrent ischaemia.
Major cardiovascular adverse events also were adjudicated according
to TIMI criteria.
Thrombin receptor-activating peptide (TRAP)-induced platelet
aggregation was performed using the turbidimetry method at those
study centres able to perform the test. A ﬁnal concentration of
15 mM TRAP was used for the test. For patients with ACS, platelet
Figure 1 E5555 chemical structure.
S. Goto et al. 2602aggregation was measured at baseline, Days 1–4 (during acute phase),
and then at Weeks 2, 4, 8, 12, and 16. For patients with CAD, platelet
aggregation was measured at baseline (Day 1), and at Weeks 2, 4, 12,
24, 26, and 28. Excluding Day 1 in ACS patients, platelet aggregation
was measured at trough level. Platelet aggregation inhibition (PAI)
was calculated post-dosing and compared with baseline.
Additional information related to safety, including adverse events,
vital signs, 12-lead ECGs, and clinical laboratory tests, was also col-
lected. Blinded 12-lead ECG was conducted by a central ECG analysis
institution (Quintiles, India).
Statistical analysis
Efﬁcacy and safety populations included all randomized patients who
showed GCP compliance, who received at least one dose of the
study drug, and who had at least one post-baseline assessment. Con-
tinuous variables are presented as summary statistics. Categorical
variables are expressed as frequencies and percentages. Analysis of
variance or Fisher’s exact test was performed to assess imbalance
among groups with respect to baseline demographics and clinical
characteristics. Exact Cochran–Armitage’s test was performed to
assess dose–response relationship with respect to incidence of
bleeding events, MACEs, and abnormal hepatic function parameters
(ALT and AST). Moreover, comparisons of the incidence between
each active group and the placebo group, and all combined active
groups and the placebo group, were assessed by relative risk. Each
relative risk estimate was accompanied by a two-sided exact
P-value and exact 95% conﬁdence limits based on the Agresti–Min
method. Fisher’s exact test was performed to compare the com-
bined active group with the placebo group with respect to the inci-
dence of adverse events and serious adverse events. The Jonckheere
test was performed to assess dose–response relationship with
respect to QTcF at the last observation carried forward
(LOCF) analysis endpoint. The Wilcoxon signed-rank sum test or
Wilcoxon test was performed for intra- or inter-group comparisons.
Signiﬁcance levels in the tests were set as follows: two-sided 5%
for dose–response relationship and comparisons, and two-sided
15% for imbalance among groups. Statistical analyses were per-
formed with SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA) and
StatXact8 (Cytel Inc., Cambridge, MA, USA). The primary objective
for both studies was to explore the safety and tolerability of
E5555. Therefore, a formal sample size for these studies was not
calculated.
All of the data analysis in this paper was conducted by the statistician
at Eisai Co., Ltd, and also conﬁrmed by SOC Co., Ltd, in Japan (the
statistical representative is Shigeru Tatsuno), a clinical research organ-
ization independent from Eisai Co., Ltd. It is these independent ana-
lyses that are presented in this paper.
Results
Of 249 patients with ACS and 271 with CAD enrolled in the study,
241 and 263 were randomized to treatment groups, respectively
(Figure 2). Baseline demographic and clinical characteristics of ran-
domized patients are shown (Table 1). Study drug discontinuation
rates after randomization in the placebo, 50, 100, and 200 mg
E5555 groups were 27.9, 33.3, 32.3, and 32.8% (P ¼ 0.641;
Cochran–Armitage’s test) in ACS patients, and 6.1, 9.5, 12.1, and
25.0% (P , 0.001; Cochran–Armitage’s test) in CAD patients,
respectively. The median date for study drug discontinuation in
the placebo group was 12 days, and in the active combined
group, it was 14 days in ACS patients.
In patients with ACS, 32.8 and 67.2% of the patients recruited as
ACS were UA and NSTEMI patients, respectively. The majority of
the patients (95.1% in placebo and 91.7% in E5555 pooled)
received both aspirin and thienopyridine as concomitant medi-
cations. Of the thienopyridines, 75.5% of the patients were
treated with clopidogrel and 24.1% of them were treated by ticlo-
pidine). In patients with CAD, however, less than half of the
patients received dual antiplatelet therapy (39.4% in placebo and
42.1% in E5555 pooled) during the study period. In patients with
CAD, over 60% reported a previous MI and over 80% reported
a previous PCI. Less than 20% of the patients with ACS reported
a previous MI or PCI.
Coronary artery disease patients with previous MI were more
frequent in the individual treatment groups than in the placebo
group, representing a potential imbalance among groups (P ¼
0.12; Fisher’s exact test). As for the other baseline demographics
and clinical characteristics in both patient populations, no group-
speciﬁc trend was noted.
Overall, there was a low incidence of CURE bleeding in both
groups of patients (Table 2). In ACS patients, major life-threatening
bleeding was seen in two patients in the placebo group (operative
haemorrhage and retroperitoneal haematoma), but in none of
the patients given E5555. No patient experienced major
non-life-threatening bleeding. Minor bleeding was seen only in
one patient in the 200 mg E5555 group (vessel puncture site
haematoma).
In CAD patients, only two patients, one in the 100 mg E5555
group and the other in the 200 mg E5555 group, experienced
CURE major and minor bleeds, respectively. The speciﬁc pro-
portions of patients with such an event were as follows: placebo:
0.0% (0/66 patient); 50 mg: 0.0% (0/63); 100 mg: 1.5% (1/66); and
200 mg: 1.5% (1/68). No signiﬁcant trend was observed in dose–
response proﬁles in this category of bleeding (P ¼ 0.38;
Cochran–Armitage test).
There were 45 and 22 patients who experienced any TIMI
bleeding (i.e. in any category including TIMI minimal bleeding) in
the ACS and CAD studies, respectively (Table 3). TIMI bleeds
due to invasive procedures were 26 of 45 in ACS and 0 of 22 in
CAD patients, thus occurring in early phase (most of the events
occurred within 15 days). There was a numerical increase in
‘any’ TIMI bleeding with the E5555 200 mg dose (ACS: 16.4%
placebo vs. 23.0% E5555, P ¼ 0.398; CAD: 4.5% placebo vs.
13.2% E5555, P ¼ 0.081) as shown in Figure 3.
In ACS patients, the incidence rates of TIMI bleeding were as
follows: placebo: 10 of 61 patients (16.4%); 50 mg: 8 of 54
(14.8%); 100 mg: 13 of 65 (20.0%); 200 mg: 14 of 61 (23.0%); the
100 and 200 mg groups showed a slightly higher rate than the
placebo group. Although there was a numerical increase in bleed-
ing in patients treated with higher doses of E5555, no signiﬁcant
dose-dependent difference was observed for the incidence of
TIMI bleeding (P ¼ 0.27; Cochran–Armitage test) and no signiﬁ-
cant difference was observed between placebo and all active com-
bined groups (P ¼ 0.61).
In all groups, no patient experienced TIMI major bleeding. TIMI
minor bleeding was seen in 2 of 65 (3.1%) in the 100 mg E5555
Safety and efﬁcacy of PAR-1 antagonist E5555 2603group (vessel puncture site haematoma and haematuria) and 1 of
61 (1.6%) in the 200 mg E5555 group (vessel puncture site haema-
toma); no patients in the placebo group or the 50 mg E5555 group
experienced such an event.
In CAD patients, the rates of TIMI bleeding were as follows:
placebo: 3 of 66 (4.5%); 50 mg: 5 of 63 (7.9%); 100 mg: 5 of 66
(7.6%); and 200 mg: 9 of 68 (13.2%). A trend was observed in
dose–response proﬁles (P ¼ 0.086; Cochran–Armitage test).
Each E5555 group showed a higher incidence than the placebo
group. However, no signiﬁcant difference was observed between
placebo and all active combined groups (P ¼ 0.22).
In all groups, no patient experienced TIMI-deﬁned major bleed-
ing. The occurrence of TIMI minor bleeding was limited to one
patient (gastrointestinal haemorrhage) in the 100 mg group.
The proportions of patients with CEC-adjudicated MACEs
during the treatment period in ACS and CAD studies are shown
(Figure 4). In ACS patients, the occurrence of MACEs was 4 of
61 (6.6%), 4 of 54 (7.4%), 3 of 65 (4.6%), and 2 of 61 (3.3%) in
Figure 2 Study protocol. We have conducted two Phase II studies for acute coronary syndrome and high-risk coronary artery disease sep-
arately. Study protocol for acute coronary syndrome is shown in (A), whereas protocol for high-risk coronary artery disease is shown in (B).
Study protocols for the two studies are similar, but differ in baseline use of antiplatelets and exposure period of the study drug. Details are
described in the Methods section.
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Table 1 Baseline demographic and clinical characteristic
Treatment group Patients with ACS Patients with CAD
Placebo(n 5 61) E5555 Placebo
(n 5 66)
E5555
All
(n 5 180)
50 mg
(n 5 54)
100 mg
(n 5 65)
200 mg
(n 5 61)
All
(n 5 197)
50 mg
(n 5 63)
100 mg
(n 5 66)
200 mg
(n 5 68)
Age (mean+SD) 64.5+9.8 65.2+8.5 65.4+8.0 66.3+8.5 63.8+8.9 65.4+7.2 66.9+7.2 66.8+7.5 66.7+7.4 67.1+6.8
Male, n (%) 50 (82.0) 144 (80.0) 47 (87.0) 52 (80.0) 45 (73.8) 55 (83.3) 175 (88.8) 58 (92.1) 59 (89.4) 58 (85.3)
Weight, kg
(mean+SD)
66.0+12.2 64.2+12.3 63.5+9.4 63.8+12.5 65.3+14.4 66.3+11.8 66.4+9.8 65.6+9.2 66.4+10.4 67.2+9.6
Previous ACS, n (%) 9 (14.8) 38 (21.1) 14 (25.9) 13 (20.0) 11 (18.0) 41 (62.1) 147 (74.6) 48 (76.2) 52 (78.8) 47 (69.1)
Previous PCI, n (%) 7 (11.5) 38 (21.1) 13 (24.1) 13 (20.0) 12 (19.7) 55 (84.6) 165 (83.8) 52 (82.5) 53 (80.3) 60 (88.2)
Previous CABG, n (%) 2 (3.3) 4 (2.2) 3 (5.6) 0 (0.0) 1 (1.6) 11 (16.7) 37 (18.8) 13 (20.6) 15 (22.7) 9 (13.2)
TIA/stroke, n (%) 4 (6.6) 16 (8.9) 7 (13.0) 4 (6.2) 5 (8.2) 13 (19.7) 29 (14.7) 9 (14.3) 11 (16.7) 9 (13.2)
Diabetes, n (%) 17 (27.9) 65 (36.1) 22 (40.7) 21 (32.3) 22 (36.1) 63 (95.5) 186 (94.4) 60 (95.2) 62 (93.9) 64 (94.1)
Hypertension, n (%) 45 (73.8) 141 (78.3) 42 (77.8) 53 (81.5) 46 (75.4) 53 (80.3) 162 (82.2) 50 (79.4) 52 (78.8) 60 (88.2)
Dyslipidaemia, n (%) 42 (68.9) 142 (78.9) 39 (72.2) 52 (80.0) 51 (83.6) 60 (90.9) 177 (89.8) 56 (88.9) 60 (90.9) 61 (89.7)
Aspirin, n (%) 61 (100) 175 (97.2) 52 (96.3) 63 (96.9) 60 (98.4) 66 (100) 197 (100) 63 (100) 66 (100) 68 (100)
Thienopyridine, n (%) 58 (95.1) 167 (92.8) 51 (94.4) 62 (95.4) 54 (88.5) 26 (39.4) 83 (42.1) 21 (33.3) 30 (45.5) 32 (47.1)
PCI in study period 55 (90.2) 155 (86.1) 46 (85.2) 54 (83.1) 55 (90.2) — — — — —
ACS, acute coronary syndrome; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; TIA, transient ischaemic attack.
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Table 2 CURE bleeding
Treatment group Patients with ACS Patients with CAD
Placebo
(n 5 61)
E5555 Placebo
(n 5 66)
E5555
All (n 5 180) 50 mg (n 5 54) 100 mg (n 5 65) 200 mg (n 5 61) Al (n 5 197) 50 mg
(n 5 63)
100 mg (n 5 66) 200 mg (n 5 68)
Any CURE bleeding 2 (3.3) 1 (0.6) (P ¼ 0.125)* 0 (0.0) (P ¼ 0.221) 0 (0.0) (P ¼ 0.151) 1 (1.6) (P ¼ 0.681) 0 (0.0) 2 (1.0) (P ¼ 0.476) 0 (0.0) (—) 1 (1.5) (P ¼ 0.528) 1 (1.5) (P ¼ 0.514)
Major bleeding 2 (3.3) 0 (0.0) (P ¼ 0.021) 0 (0.0) (P ¼ 0.221) 0 (0.0) (P ¼ 0.151) 0 (0.0) (P ¼ 0.209) 0 (0.0) 1 (0.5) (P ¼ 0.728) 0 (0.0) (—) 1 (1.5) (P ¼ 0.528) 0 (0.0) (—)
Life-threatening 2 (3.3) 0 (0.0) (P ¼ 0.021) 0 (0.0) (P ¼ 0.221) 0 (0.0) (P ¼ 0.151) 0 (0.0) (P ¼ 0.209) 0 (0.0) 1 (0.5) (P ¼ 0.728) 0 (0.0) (—) 1 (1.5) (P ¼ 0.528) 0 (0.0) (—)
Non-life-threatening 0 (0.0) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) (—)
Minor bleeding 0 (0.0) 1 (0.6) (P ¼ 0.727) 0 (0.0) (—) 0 (0.0) (—) 1 (1.6) (P ¼ 0.528) 0 (0.0) 1 (0.5) (P ¼ 0.728) 0 (0.0) (—) 0 (0.0) (—) 1 (1.5) (P ¼ 0.514)
Cochran–Armitage
test**
P ¼ 0.702 P ¼ 0.379
*P-values vs. placebo group.
**P-values show the dose relationship of any CURE bleeding.
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Table 3 TIMI bleeding
Treatment group Patients with ACS Patients with CAD
Placebo
(n 5 61)
E5555 Placebo
(n 5 66)
E5555
All (n 5 180) 50 mg (n 5 54) 100 mg (n 5 65) 200 mg (n 5 61) All (n 5 197) 50 mg (n 5 63) 100 mg (n 5 66) 200 mg (n 5 68)
Any TIMI bleeding 10 (16.4) 35 (19.4) (P ¼ 0.609)* 8 (14.8) (P ¼ 0.850) 13 (20.0) (P ¼ 0.692) 14 (23.0) (P ¼ 0.398) 3 (4.5) 19 (9.6) (P ¼ 0.219) 5 (7.9) (P ¼ 0.530) 5 (7.6) (P ¼ 0.531) 9 (13.2) (P ¼ 0.081)
Major bleeding 0 (0.0) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) (—) 0 (0.0) (—)
Minor bleeding 0 (0.0) 3 (1.7) (P ¼ 0.380) 0 (0.0) (—) 2 (3.1) (P ¼ 0.222) 1 (1.6) (P ¼ 0.528) 0 (0.0) 1 (0.5) (P ¼ 0.728) 0 (0.0) (—) 1 (1.5) (P ¼ 0.528) 0 (0.0) (—)
Minimal bleeding 10 (16.4) 32 (17.8) (P ¼ 0.824) 8 (14.8) (P ¼ 0.850) 11 (16.9) (P ¼ 0.998) 13 (21.3) (P ¼ 0.526) 3 (4.5) 18 (9.1) (P ¼ 0.244) 5 (7.9) (P ¼ 0.530) 4 (6.1) (P ¼ 0.791) 9 (13.2) (P ¼ 0.081)
With medical
attention
4 (6.6) 6 (3.3) (P ¼ 0.303) 1 (1.9) (P ¼ 0.252) 1 (1.5) (P ¼ 0.173) 4 (6.6) (P ¼ 1.000) 1 (1.5) 2 (1.0) (P ¼ 0.832) 1 (1.6) (P ¼ 1.000) 0 (0.0) (P ¼ 0.528) 1 (1.5) (P ¼ 1.000)
Without medical
attention
6 (9.8) 26 (14.4) (P ¼ 0.371) 7 (13.0) (P ¼ 0.671) 10 (15.4) (P ¼ 0.514) 9 (14.8) (P ¼ 0.531) 2 (3.0) 16 (8.1) (P ¼ 0.171) 4 (6.3) (P ¼ 0.530) 4 (6.1) (P ¼ 0.531) 8 (11.8) (P ¼ 0.056)
Cochran–Armitage
test**
P ¼ 0.266 P ¼ 0.086
Medical attention: any bleeding that requires medical treatment, surgical treatment, or laboratory evaluation and does not meet criteria for major or minor bleeding.
*P-values vs. placebo group.
**P-values show the dose relationship of any TIMI bleeding.
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6the placebo, 50, 100, and 200 mg E5555 groups, respectively. The
percentage occurrence of MACEs in the active combined group
and placebo group (5.0 vs. 6.6%, respectively; relative risk 0.76;
95% CI 0.257–2.606) was not signiﬁcantly different (P ¼ 0.73).
The most frequent MACE was recurrent ischaemia, and no cardi-
ovascular death occurred in any group. The second most frequent
MACE was MI, with occurrence of 2 of 61 (3.3%), 0 of 54 (0.0%), 1
of 65 (1.5%), and 1 of 61 (1.6%) in the placebo, 50, 100, and
200 mg E5555 groups, respectively. Ischaemic stroke induced by
embolism was seen only in the 200 mg E5555 group in 1 of 61
patients (1.6%).
In CAD patients, the occurrence of MACEs was 3 of 66 (4.5%),
0 of 63 (0.0%), 1 of 66 (1.5%), and 1 of 68 (1.5%) in the placebo,
50, 100, and 200 mg E5555 groups, respectively. The rate of
Figure 3 CEC-adjudicated TIMI bleeding by category. CEC-adjudicated TIMI bleeding in placebo, E5555 pooled, and each dose tested of
E5555, as shown. Any TIMI bleeding, including minimal bleeding not requiring medical attention, occurred more in patients treated
by E5555. However, TIMI bleeding requiring medical attention or more severe bleeding did not increase even when patients were treated
by E5555. Details are described in the Results section.
Figure 4 CEC-adjudicated MACEs by category. CEC-adjudicated each category of major cardiovascular adverse events in placebo, E5555
pooled, and each dose tested, as shown. Details are described in the Results section.
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in the placebo group (1.0 vs. 4.5%, respectively; relative risk 0.22;
95% CI 0.041–1.109), although this was not statistically signiﬁcant
(P ¼ 0.066). All MACEs were recurrent ischaemia events and no
cardiovascular death, MI, or stroke occurred in any group.
The PAI induced by 15 mM TRAP is shown in Figure 5. In both
studies, the mean PAI in patients at trough treated with 100 or
200 mg E5555 was over 90%, and the mean PAI at trough in
patients treated with 50 mg was 20–50% in ACS patients and
50–60% in CAD patients. In ACS patients treated with E5555,
the mean PAI reached .80% at 3–6 h after administration of
the 400 mg E5555 loading dose. In all of the E5555 treatment
groups, the mean PAI markedly decreased after the completion
of study drug administration, and the effect on PAI completely dis-
appeared at 2 weeks after the completion of study drug.
The incidences of adverse events, serious adverse events, and
higher frequency adverse events are shown in Tables 4 and 5.
Overall, there were signiﬁcantly more treatment-related adverse
events in patients treated with E5555 than in patients receiving
placebo (44.4 vs. 27.9%, respectively, in ACS patients, P ¼ 0.024;
32.0 vs. 13.6%, respectively, in CAD patients, P ¼ 0.003).
In both studies, the most common adverse event related to
study drug was abnormal liver function. For individual hepatic func-
tion parameters (ALT and AST), the proportion of patients with an
abnormally high level was calculated for all groups using the FDA
guideline ‘Guidance for Industry, Drug-induced Liver Injury: Pre-
marketing Clinical Evaluation’ (Figure 6).
In ACS patients, the proportions of patients with the ALT level
.3×ULN were 0.0% (0/60), 0.0% (0/54), 6.2% (4/65), and 14.8%
(9/61) in the placebo, 50, 100 and 200 mg E5555 groups, respect-
ively (in the 200 mg E5555 group, P ¼ 0.001). In the placebo and
50 mg E5555 groups, no patient met this criterion. There was a sig-
niﬁcant increase for the rate of ALT elevation in the active com-
bined group vs. the placebo group (7.2 vs. 0.0%, respectively;
P ¼ 0.034). The proportions of patients with the AST level
.3× ULN were 1.7% (1/60), 0.0% (0/54), 1.5% (1/65), and 9.8%
(6/61) in the placebo, 50, 100, and 200 mg E5555 groups, respect-
ively (in the 200 mg E5555 group, relative risk 5.902; 95% CI
0.938–75.547, P ¼ 0.062). In the 50 mg E5555 group, no patient
met this criterion. The rate of AST elevation in the active com-
bined group vs. the placebo group was 3.9 vs. 1.7%, respectively;
relative risk 2.333; 95% CI 0.380–29.538, P ¼ 0.447.
In CAD patients, the proportions of patients with an ALT level
.3× ULN were 0.0% (0/66), 1.6% (1/63), 1.5% (1/66), and 11.8%
(8/68) in the placebo, 50, 100, and 200 mg E5555 groups, respect-
ively (in the 200 mg E5555 group, P ¼ 0.004). In the placebo group,
no patient met this criterion. There was a non-signiﬁcant increase
for the rate of ALT elevation in the active combined group vs. the
placebo group (5.1 vs. 0.0%, respectively; P ¼ 0.061). The pro-
portions of patients with an AST level .3× ULN were 0.0% (0/
66), 1.6% (1/63), 0.0% (0/66), and 8.8% (6/68) in the placebo, 50,
100, and 200 mg E5555 groups, respectively (in the 200 mg
E5555 group, P ¼ 0.012). In the 100 mg and placebo groups, no
patient met this criterion. The rate of AST elevation in the active
Figure 5 Inhibition of platelet aggregation induced thrombin receptor-activating peptide (TRAP) at a ﬁnal concentration of 15 mM is shown in
both acute coronary syndrome and coronary artery disease patients. In the upper right panel, detailed changes in the inhibition of
TRAP-induced platelet aggregation within 3 days after drug administration are shown. Each point represents mean+SD of sample tested.
Details are described in the Results section.
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Table 4 Incidence of overall adverse events
Treatment group Patients with ACS Patients with CAD
Placebo
(n 5 61)
E5555 Placebo
(n 5 66)
E5555
All (n 5 180) 50 mg (n 5 54) 100 mg (n 5 65) 200 mg (n 5 61) All (n 5 197) 50 mg (n 5 63) 100 mg (n 5 66) 200 mg (n 5 68)
Adverse events (AE) 53 (86.9) 168 (93.3) (P ¼ 0.175) 48 (88.9) (P ¼ 0.782) 60 (92.3) (P ¼ 0.386) 60 (98.4) (P ¼ 0.032) 48 (72.7) 147 (74.6) (P ¼ 0.748) 44 (69.8) (P ¼ 0.845) 48 (72.7) (P ¼ 1.000) 55 (80.9) (P ¼ 0.308)
Treatment- related AE 17 (27.9) 80 (44.4) (P ¼ 0.024) 17 (31.5) (P ¼ 0.687) 34 (52.3) (P ¼ 0.006) 29 (47.5) (P ¼ 0.039) 9 (13.6) 63 (32.0) (P ¼ 0.003) 17 (27.0) (P ¼ 0.078) 14 (21.2) (P ¼ 0.358) 32 (47.1) (P , 0.001)
Serious AE 9 (14.8) 26 (14.4) (P ¼ 1.000) 9 (16.7) (P ¼ 0.802) 8 (12.3) (P ¼ 0.796) 9 (14.8) (P ¼ 1.000) 7 (10.6) 18 (9.1) (P ¼ 0.808) 4 (6.3) (P ¼ 0.531) 6 (9.1) (P ¼ 1.000) 8 (11.8) (P ¼ 1.000)
Treatment-related serious
AE
3 (4.9) 9 (5.0) (P ¼ 1.000) 1 (1.9) (P ¼ 0.621) 3 (4.6) (P ¼ 1.000) 5 (8.2) (P ¼ 0.717) 1 (1.5) 5 (2.5) (P ¼ 1.000) 1 (1.6) (P ¼ 1.000) 1 (1.5) (P ¼ 1.000) 3 (4.4) (P ¼ 0.619)
Data are expressed as number of patients (% total). P-values vs. placebo group.
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Table 5 Incidence of frequent adverse events
Treatment group Patients with ACS Patients with CAD
Placebo
(n 5 61)
E5555 Placebo
(n 5 66)
E5555
All (n 5 180) 50 mg (n 5 54) 100 mg (n 5 65) 200 mg (n 5 61) All (n 5 197) 50 mg (n 5 63) 100 mg (n 5 66) 200 mg (n 5 68)
Nasopharyngitis 10 (16.4) 17 (9.4) (P ¼ 0.159) 8 (14.8) (P ¼ 1.000) 4 (6.2) (P ¼ 0.090) 5 (8.2) (P ¼ 0.269) 14 (21.2) 53 (26.9) (P ¼ 0.416) 16 (25.4) (P ¼ 0.677) 19 (28.8) (P ¼ 0.421) 18 (26.5) (P ¼ 0.545)
Hepatic function disorder 7 (11.5) 42 (23.3) (P ¼ 0.064) 5 (9.3) (P ¼ 0.767) 19 (29.2) (P ¼ 0.015) 18 (29.5) (P ¼ 0.023) 1 (1.5) 20 (10.2) (P ¼ 0.032) 2 (3.2) (P ¼ 0.613) 5 (7.6) (P ¼ 0.207) 13 (19.1) (P ¼ 0.001)
Insomnia 10 (16.4) 17 (9.4) (P ¼ 0.159) 4 (7.4) (P ¼ 0.164) 5 (7.7) (P ¼ 0.171) 8 (13.1) (P ¼ 0.799) 3 (4.5) 1 (0.5) (P ¼ 0.049) 0 (0.0) (P ¼ 0.244) 1 (1.5) (P ¼ 0.619) 0 (0.0) (P ¼ 0.116)
Upper respiratory tract
inﬂammation
1 (1.6) 1 (0.6) (P ¼ 0.442) 0 (0.0) (P ¼ 1.000) 0 (0.0) (P ¼ 0.484) 1 (1.6) (P ¼ 1.000) 3 (4.5) 12 (6.1) (P ¼ 0.767) 3 (4.8) (P ¼ 1.000) 7 (10.6) (P ¼ 0.324) 2 (2.9) (P ¼ 0.678)
Headache 5 (8.2) 21 (11.7) (P ¼ 0.633) 6 (11.1) (P ¼ 0.753) 5 (7.7) (P ¼ 1.000) 10 (16.4) (P ¼ 0.269) 3 (4.5) 4 (2.0) (P ¼ 0.372) 2 (3.2) (P ¼ 1.000) 0 (0.0) (P ¼ 0.244) 2 (2.9) (P ¼ 0.678)
Constipation 9 (14.8) 27 (15.0) (P ¼ 1.000) 4 (7.4) (P ¼ 0.250) 11 (16.9) (P ¼ 0.810) 12 (19.7) (P ¼ 0.632) 1 (1.5) 4 (2.0) (P ¼ 1.000) 1 (1.6) (P ¼ 1.000) I (1.5) (P ¼ 1.000) 2 (2.9) (P ¼ 1.000)
Back pain 10 (16.4) 24 (13.3) (P ¼ 0.530) 7 (13.0) (P ¼ 0.793) 7 (10.8) (P ¼ 0.437) 10 (16.4) (P ¼ 1.000) 4 (6.1) 6 (3.0) (P ¼ 0.275) 4 (6.3) (P ¼ 1.000) 2 (3.0) (P ¼ 0.680) 0 (0.0) (P ¼ 0.056)
Chest discomfort 11 (18.0) 27 (15.0) (P ¼ 0.549) 10 (18.5) (P ¼ 1.000) 6 (9.2) (P ¼ 0.194) 11 (18.0) (P ¼ 1.000) 1 (1.5) 3 (1.5) (P ¼ 1.000) 2 (3.2) (P ¼ 0.613) 1 (1.5) (P ¼ 1.000) 0 (0.0) (P ¼ 0.492)
Chest pain 8 (13.1) 19 (10.6) (P ¼ 0.639) 3 (5.6) (P ¼ 0.213) 9 (13.8) (P ¼ 1.000) 7 (11.5) (P ¼ 1.000) 2 (3.0) 3 (1.5) (P ¼ 0.601) 1 (1.6) (P ¼ 1.000) 1 (1.5) (P ¼ 1.000) 1 (1.5) (P ¼ 0.616)
Pyrexia 3 (4.9) 23 (12.8) (P ¼ 0.098) 5 (9.3) (P ¼ 0.471) 10 (15.4) (P ¼ 0.077) 8 (13.1) (P ¼ 0.204) 1 (1.5) 2 (1.0) (P ¼ 1.000) 0 (0.0) (P ¼ 1.000) 0 (0.0) (P ¼ 1.000) 2 (2.9) (P ¼ 1.000)
Data are expressed as number of patients (% total). P-values vs. placebo group.
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9combined group vs. the placebo group was 3.6 vs. 0.0%, respect-
ively; P ¼ 0.133.
In detail, 6 of 7 in placebo, 5 of 5 at 50 mg, 19 of 19 at 100 mg,
and 16 of 18 cases of hepatic disorder at 200 mg occurred in ACS
patients treated either by ticlopidine or clopidogrel. On the other
hand, 0 of 1 in placebo, 0 of 2 at 50 mg, 0 of 5 at 100 mg, and 4 of
13 cases at 200 mg occurred in CAD patients who were also
treated by thienopyridine.
There was no patient who experienced elevation of AST or ALT
.3× ULN with elevation of total bilirubin .2× ULN.
There were also dose-related effects on QTcF noted with
E5555. In ACS patients at Week 12 LOCF, the changes in QTcF
from baseline were 28.3+3.6, 25.1+3.4, 26.3+3.1, and
20.9+4.3 ms, in the placebo, 50, 100, and 200 mg E5555
groups, respectively (i.e. the QTcF shortened from baseline to
12 weeks in placebo in these ACS patients, but shortened less in
the treated groups). There was a trend towards a difference
between the placebo and 200 mg E5555 groups (P ¼ 0.066), and
there was a trend towards statistically signiﬁcant dose-dependent
QTcF prolongation (P ¼ 0.074; Jonckheere–Terpstra’s test). In
CAD patients at Week 24 LOCF, the changes from baseline
in QTcF were 1.4+2.4, 4.1+2.9, 6.1+2.2, and 6.3+2.9 ms in
the placebo, 50, 100, and 200 mg E5555 groups, respectively.
There were signiﬁcant prolongations in the 100 mg (P ¼ 0.015)
and 200 mg (P ¼ 0.037) groups in comparison with the placebo
group. There was a statistically signiﬁcant dose-dependent QTcF
prolongation (P ¼ 0.026; Jonckheere–Terpstra’s test).
Discussion
In these two multicentre, randomized, double-blind, placebo-
controlled Phase II studies of Japanese patients, the orally active
PAR-1 antagonist E5555 showed a numerical increase in ‘nuisance’
bleeding events dose-dependently, but did not increase clinically
signiﬁcant bleeding events in ACS or CAD. There was a higher inci-
dence of any bleeding events in ACS patients when compared with
CAD, which might be due to more invasive procedures or higher
use of thienopyridines, but might partly be due to the loading dose
of E5555 used in the ACS trial. Clinically signiﬁcant bleeding events
were relatively uncommon in patients receiving concomitant
aspirin and thienopyridine, as was the case in the majority of the
patients in both studies.
The combined E5555 treatment group in the ACS patients, and
all individual E5555 treatment groups in the CAD patients, showed
a numerically lower incidence of MACEs than their respective
placebo groups. These data highlight the potential of E5555 to
reduce ischaemic events in ACS and CAD patients. However,
the incidence of MACEs in all groups was low and the study was
not powered to demonstrate signiﬁcant effects of E5555 vs.
placebo on MACEs. Therefore, additional, adequately powered
studies are required to evaluate the effects of E5555 on MACEs
more fully. Of note, no CV deaths and a low incidence of
MACEs were observed in both studies, and it is generally known
that CV death and ischaemic event rates would be low in Japan.
3,24
In patients with ACS, the E5555 loading dose (400 mg) rapidly
inhibited platelet aggregation, and this effect was maintained with
100 and 200 mg daily up to Week 12. E5555 showed .90% inhi-
bition of the platelet thrombin receptor at 100 and 200 mg. More-
over, the effect of PAI disappeared after the completion or
discontinuation of E5555 administration. This suggests that the
PAI effect of E5555 may be reversible and related to its plasma
concentration. E5555 inhibited platelet aggregation for up to 24
weeks in patients with CAD at all doses tested. These data demon-
strate a signiﬁcant pharmacodynamic effect of E5555 associated
with inhibition of platelet aggregation, and this effect was both
rapid in onset and sustained.
Figure 6 Proportions of patients with high level of hepatic function parameter. Proportions of patients who experienced hepatic dysfunction
deﬁned by alanine aminotransferase and aspartate aminotransferase three times more than the upper limit of normal are shown. Details are
described in the Results section.
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tion tests at a dose of 200 mg than at lower doses. In CAD patients
especially, the discontinuation rate in the 200 mg E5555 group was
higher than the placebo group (25.0 vs. 6.1%, respectively), and this
was due to the occurrence of liver dysfunction. The incidence of
liver function test abnormalities in ACS patients was much
higher than in CAD patients. Most ACS patients were treated by
thienopyridines. Some ACS patients who experienced liver func-
tion abnormalities may be due to the treatment by thienopyridine
because the incidence of liver function abnormalities in the placebo
group was much higher than in the placebo group in CAD patients.
Regardless, our results demonstrating dose-dependent increases in
hepatic dysfunction with the use of E5555 raise caution of hepatic
disorders induced by E5555. Since the number of patients exposed
to E5555 in the studies described in this manuscript is small, any
future studies would need to consider Hy’s law and the potential
for serious hepatic toxicity.
25 There was also a statistically signiﬁcant
QT prolongation in the groups receiving the two higher E5555
doses compared with the placebo group. The degree of QT pro-
longation and liver dysfunction with the two higher doses of
E5555 should be carefully considered in any future studies.
Despite rigorous treatment with currently available antiplatelet
agents, patients with ACS and CAD continue to experience major
atherothrombotic events, indicating that there is still a need for
new antiplatelet therapies. The current standard of care for ACS
patients is dual antiplatelet therapy with aspirin and clopidogrel,
although studies show that newer P2Y12 inhibitors, including prasu-
grel and ticagrelor, are more effective than clopidogrel.
26,27 Limit-
ations of clopidogrel include relatively slow onset of effect, low
PAI in many patients, inter-individual variability in response, and irre-
versible P2Y12 binding that prevents rapid offset of effect. Novel
antiplatelet agents targeting the thrombin-speciﬁc pathway, such as
the PAR-1 antagonist E5555, have great potential to fulﬁl some of
the current limitations of dual antiplatelet therapy by providing
rapid onset of action, enhanced inhibition of platelet aggregation,
as well as targeting an additional platelet activation pathway. This
may allow the therapy to be added on to existing treatments to
further minimize the risk of atherothrombotic events without signiﬁ-
cantly increasing bleeding rates. Recently, dabigatran, an oral direct
thrombin inhibitor, showed a lower rate of stroke compared with
warfarin in atrial ﬁbrillation patients.
28
Effective antiplatelet treatment is a balance between athero-
thrombotic risk and bleeding risk. It has been clearly demonstrated
that greater platelet inhibition may produce better clinical
outcome by reducing ischaemic events, but at the risk of higher
bleeding when targeting P2Y12.
26,29 It is well known that patients
deﬁcient in P2Y12 have a bleeding disorder,
30 whereas no PAR-1
deﬁcient patients were reported as having a bleeding disorder.
Our study showed that there was an apparent dose–response in
bleeding and adverse events, including elevation of enzyme levels
in liver function tests and QTcF, with E5555 compared with
placebo. Platelet inhibition measured by the TRAP method was
about 50% with 50 mg E5555, whereas it was .90% with 100
and 200 mg E5555.
These studies were conducted as the ﬁrst investigation and
exploratory pilot studies with Japanese patients. Therefore, these
studies were limited in their ability to detect any statistical differ-
ences in safety and efﬁcacy between the placebo and E5555
groups or combined active group. For that reason, no adjustments
were made for multiple comparisons.
Conclusion
In conclusion, E5555 added to standard antiplatelet therapy may
have potential for reducing MACEs in patients with ACS or
high-risk CAD, without increasing the incidence of clinically sig-
niﬁcant bleeding. The issues of QT prolongation and liver dysfunc-
tion with E5555 would need to be considered in any potential
future studies. Nevertheless, antagonism of the PAR-1 receptor
appears to be an attractive pathway for the treatment of
atherothrombosis.
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dai Memorial Hospital), Yasunobu Hirata (The University of Tokyo
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Mashio Nakamura (Mie University Hospital), Akio Kimura (Kinki
University Hospital), Nobuhisa Awata (Osaka Medical Center for
Cancer and Cardiovascular Diseases), Kazuteru Fujimoto (National
Hospital Organization Kumamoto Medical Center), Hisayoshi
Osawa (Sapporo Central Hospital), Hitoshi Oiwa (Oji General
Hospital), Takefumi Ozaki (Chitose City Hospital), Shinichi
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Classiﬁcation of bleeding severity (CURE and TIMI criteria)
Severity CURE criteria TIMI criteria
Type Description
Major Life-threatening Fatal
Symptomatic intracranial haemorrhage
Causes haemoglobin drop .5 g/dL
Necessitates transfusion of ≥4 U of packed
redbloodcellforbloodtransfusion(PRBC)
Causes hypotension requiring administration
of an inotropic agent or a surgical
intervention
(1) If it is intracranial, or
(2) clinicallysigniﬁcantovert signsof haemorrhage associated with a drop
in haemoglobin of .5 g/dL (or, when haemoglobin is not available, an
absolute drop in haematocrit of .15%)
(3) If CABG related: fatal bleeding or perioperative intracranial bleeding
or reoperation following closure of the sternotomy incision for the
purpose of controlling bleeding or transfusion of .5 U of whole
blood or PRBC within a 48 h period (cell saver transfusion will not be
counted in calculations of blood products) orchesttube output .2L
within a 24 h period Non-life-threatening Necessitates transfusion of 2–3 U of PRBC
Intraocular haemorrhage
Causes other signiﬁcant disability
Minor Other haemorrhages that lead to the
interruption of the study drug
Any clinically overt sign of haemorrhage (including imaging) that is
associated with a fall in haemoglobin of 3 to ≤5 g/dL (or, when
haemoglobin is not available, a fall in haematocrit of 9 to ≤15%)
Minimal None Any clinically overt sign of haemorrhage (including imaging) that is
associated with a fall in haemoglobin ,3 g/dL (or, when haemoglobin
is not available, a fall in haematocrit of ,9%)
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